Go online to PeerView.com/AWT860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, hematology and oncology experts discuss the emergence of novel, orally administered therapeutics as management options for patients with B-cell lymphoma. This activity also features the perspectives of a patient with small lymphocytic lymphoma and his experience of oral therapy during the course of his therapeutic journey. Upon completion of this activity, participants will be able to: Review updated efficacy and safety data on novel oral agent classes, including BTK and PI3K inhibitors, and immunomodulators, for B-cell non-Hodgkin lymphomas (NHLs) such as CLL, MCL, WM, and other indolent or aggressive B-cell malignancies, Apply optimal strategies to educate patients on therapeutic expectations, and adherence and safety issues regarding oral treatment regimens for B-cell NHL, Collaborate with other members of the hematology-oncology team to manage dosing and develop effective side effect prevention and management strategies in patients with B-cell NHL receiving oral therapies.